WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, August 10, 2004

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ	
☐	L3	(intermittent adj claudication or (skeletal adj muscle adj injur$ same ischemia)) and (GLP-1 or glucagon same like adj peptide adj 1 or exendin$)	35
☐	L2	(intermittent adj claudication or (skeletal adj muscle adj injur$ same ischemia)) same (GLP-1 or glucagon same like adj peptide adj 1 or exendin$)	3
☐	L1	intermittent adj claudication or (skeletal adj muscle adj injur$ same ischemia) same (GLP-1 or glucagon same like adj peptide adj 1 or exendin$)	1667

END OF SEARCH HISTORY

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 20030073626 A1

Using default format because multiple data bases are involved.

L2: Entry 1 of 3 File: PGPB Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030073626
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030073626 A1

TITLE: Compositions and methods for treating peripheral vascular disease

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hathaway, David R.	Lincoln	NE	US	
Coolidge, Thomas R.	Falls Village	CT	US	

US-CL-CURRENT: 514/12; 424/722, 424/94.4, 514/18, 514/23, 514/419, 514/458

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

☐ 2. Document ID: US 20030040469 A1

L2: Entry 2 of 3 File: PGPB Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030040469
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030040469 A1

TITLE: Lowering serum lipids

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Knudsen, Liselotte Bjerre	Valby		DK	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

☐ 3. Document ID: US 20030073626 A1

L2: Entry 3 of 3 File: DWPI Apr 17, 2003

DERWENT-ACC-NO: 2003-677986
DERWENT-WEEK: 200365

TITLE: Method for the treatment or prevention of intermittent claudication or skeletal muscle injury caused by ischemia and/or reperfusion in a human subject, comprises administration of a glucagon-like peptide-1 molecule

INVENTOR: COOLIDGE, T R; HATHAWAY, D R

PRIORITY-DATA: 2002US-0091258 (March 5, 2002), 1999US-0302596 (April 30, 1999), 2001US-0851738 (May 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030073626 A1	April 17, 2003		012	A61K038/17

INT-CL (IPC): A61 K 31/355; A61 K 31/405; A61 K 31/70; A61 K 33/00; A61 K 38/06; A61 K 38/17; A61 K 38/44

Term	Documents
INTERMITTENT	116068
INTERMITTENTS	32
CLAUDICATION	2076
CLAUDICATIONS	3
SKELETAL	37451
SKELETALS	8
MUSCLE	117327
MUSCLES	42727
ISCHEMIA	26322
ISCHEMIUM	0
((INTERMITTENT ADJ CLAUDICATION OR (SKELETAL ADJ MUSCLE ADJ INJUR$ SAME ISCHEMIA)) SAME (GLP-1 OR GLUCAGON SAME LIKE ADJ PEPTIDE ADJ 1 OR EXENDIN$)).PGPB,USPT,EPAB,DWPI,TDBD.	3

There are more results than shown above. Click here to view the entire set.

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 35 of 35 returned.

☐ 1. Document ID: US 20040082646 A1

Using default format because multiple data bases are involved.

L3: Entry 1 of 35 File: PGPB Apr 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040082646
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040082646 A1

TITLE: Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases

PUBLICATION-DATE: April 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rytved, Klaus Asger	Bagsvaerd		DK	
Dragsted, Nils	Stenlose		DK	
Nyborg, Niels Chresten Berg	Horsholm		DK	
Iversen, Lars	Hvidovre		DK	
Kristiansen, Marit	Soborg		DK	

US-CL-CURRENT: 514/423; 514/424, 514/426

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 20040082641 A1

L3: Entry 2 of 35 File: PGPB Apr 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040082641
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040082641 A1

TITLE: Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases

PUBLICATION-DATE: April 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rytved, Klaus Asger	Bagsvaerd		DK	
Dragsted, Nils	Stenlose		DK	
Nyborg, Niels Chresten Berg	Horsholm		DK	
Iversen, Lars	Hvidovre		DK	

Kristiansen, Marit Soborg DK

US-CL-CURRENT: 514/408; 514/423, 514/424, 514/426

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 3. Document ID: US 20040077689 A1

L3: Entry 3 of 35 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040077689
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040077689 A1

TITLE: Abc expression promoters

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sugiyama, Yasuo	Kawanishi-shi		JP	
Fuse, Hiromatsu	Tsukuba-shi		JP	
Hirakata, Masao	Kobe-shi		JP	
Tozawa, Ryuichi	Toyonaka-shi		JP	

US-CL-CURRENT: 514/342; 514/352, 514/354, 514/369, 514/423, 514/426, 514/567

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 4. Document ID: US 20040072874 A1

L3: Entry 4 of 35 File: PGPB Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072874
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040072874 A1

TITLE: N-substituted-2-oxodihydropyridine derivatives

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sato, Nagaaki	Ibaraki		JP	
Ando, Makoto	Ibaraki		JP	
Ishikawa, Shiho	Ibaraki		JP	
Nagase, Tsuyoshi	Ibaraki		JP	
Nagai, Keita	Ibaraki		JP	
Kanatani, Akio	Ibaraki		JP	

US-CL-CURRENT: 514/341; 546/274.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 5. Document ID: US 20040054177 A1

L3: Entry 5 of 35 File: PGPB Mar 18, 2004

PGPUB-DOCUMENT-NUMBER: 20040054177
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040054177 A1

TITLE: Novel benzimidazole derivatives

PUBLICATION-DATE: March 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Otake, Norikazu	Tsukuba-shi		JP	
Moriya, Minoru	Tsukuba-shi		JP	
Ogino, Yoshio	Tsukuba-shi		JP	
Matsuda, Kenji	Tokyo		JP	
Nagae, Yoshikazu	Tsukuba-shi		JP	
Kanatani, Akio	Tsukuba-shi		JP	
Fukami, Takehiro	Tsukuba-shi		JP	

US-CL-CURRENT: 544/230; 546/18, 548/300.7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 6. Document ID: US 20040053889 A1

L3: Entry 6 of 35 File: PGPB Mar 18, 2004

PGPUB-DOCUMENT-NUMBER: 20040053889
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040053889 A1

TITLE: Pharmaceutical use of boronic acids and esters thereof

PUBLICATION-DATE: March 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ebdrup, Soren	Roskilde		DK	
Vedso, Per	Frederiksberg		DK	
Jacobsen, Poul	Slangerup		DK	

US-CL-CURRENT: 514/64

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 7. Document ID: US 20040039033 A1

L3: Entry 7 of 35 File: PGPB Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040039033
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040039033 A1

TITLE: (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Atwal, Karnail S.	Pennington	NJ	US	
Grover, Gary J.	Stockton	NJ	US	
Ding, Charles Z.	Dallas	TX	US	
Stein, Philip D.	Pennington	NJ	US	
Lloyd, John	Yardley	PA	US	
Ahmad, Saleem	Wall	NJ	US	
Hamann, Lawrence G.	Cherry Hill	NJ	US	
Green, David	Haverhill	MA	US	
Ferrara, Francis N.	Bedminster	NJ	US	

US-CL-CURRENT: 514/357; 514/367, 514/408, 514/438, 514/470, 514/524, 546/330, 548/205, 548/577, 549/491, 549/75, 558/422

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 8. Document ID: US 20040009972 A1

L3: Entry 8 of 35 File: PGPB Jan 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040009972
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040009972 A1

TITLE: Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase

PUBLICATION-DATE: January 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ding, Charles Z.	Plano	TX	US	
Hamann, Lawrence G.	Cherry Hill	NJ	US	
Stein, Philip D.	Pennington	NJ	US	

Pudzianowski, Andrew T. Yardley PA US

US-CL-CURRENT: 514/221; 540/573

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 9. Document ID: US 20030236272 A1

L3: Entry 9 of 35 File: PGPB Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030236272
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030236272 A1

TITLE: Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Carr, Richard David	Vaerlose		DK	

US-CL-CURRENT: 514/263.2; 514/263.22, 514/423

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 10. Document ID: US 20030224501 A1

L3: Entry 10 of 35 File: PGPB Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224501
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030224501 A1

TITLE: Bone morphogenic protein polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Young, Paul E.	Gaithersburg	MD	US	
Ruben, Steven M.	Brookeville	MD	US	

US-CL-CURRENT: 435/226; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 11. Document ID: US 20030220255 A1

L3: Entry 11 of 35 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220255
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030220255 A1

TITLE: GLP-1 agonist and cardiovascular complications

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Knudsen, Liselotte Bjerre	Valby		DK	
Rolin, Bidda Charlotte	Naerum		DK	
Carr, Richard David	Vaerlose		DK	
Selmer, Johan	Farum		DK	
Larsen, Jens	Fredensborg		DK	
Elbrond, Bodil	Kobenhavn		DK	
Nielsen, Lars Bo	Virum		DK	
Christoffersen, Christina	Kobenhavn		DK	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 12. Document ID: US 20030215836 A1

L3: Entry 12 of 35 File: PGPB Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215836
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030215836 A1

TITLE: Bone morphogenic protein polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Young, Paul E.	Gaithersburg	MD	US	
Ruben, Steven M.	Brookeville	MD	US	

US-CL-CURRENT: 435/6; 424/94.65, 435/226, 435/320.1, 435/325, 435/69.1, 435/7.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 13. Document ID: US 20030166690 A1

L3: Entry 13 of 35 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166690
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166690 A1

TITLE: Use of compounds for decreasing activity of hormone-sensitive

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ebdrup, Soren	Roskilde		DK	
de Jong, Johannes Cornelis	Bagsvaerd		NL	
Jacobsen, Poul	Slangerup		DK	
Hansen, Holger Claus	Vaerlose		DK	
Vedso, Per	Frederiksberg		DK	

US-CL-CURRENT: 514/354; 514/423, 514/521, 514/599, 514/625

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 14. Document ID: US 20030166644 A1

L3: Entry 14 of 35 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166644
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166644 A1

TITLE: Compounds and uses thereof for decreasing activity of hormone-sensitive lipase

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ebdrup, Soren	Roskilde		DK	
de Jong, Johannes Cornelis	Bagsvaerd		DK	
Jacobsen, Poul	Slangerup		DK	
Hansen, Holger Claus	Vaerlose		DK	
Vedso, Per	Frederiksberg		DK	

US-CL-CURRENT: 514/227.5; 514/227.8, 514/235.5, 514/237.5, 514/241, 514/252.02, 514/252.11, 514/252.14, 514/253.13, 514/255.01, 514/317, 514/318, 514/478, 544/124, 544/209, 544/238, 544/295, 544/357, 544/360, 544/59, 544/60, 546/194, 546/226

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 15. Document ID: US 20030138795 A1

L3: Entry 15 of 35 File: PGPB Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030138795
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030138795 A1

TITLE: Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, BGS-8, expressed highly in immune tissue

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wu, Shujian	Langhorne	PA	US	
Lee, Liana M.	North Brunswick	NJ	US	
Feder, John N.	Belle Mead	NJ	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

---

☐ 16. Document ID: US 20030096827 A1

L3: Entry 16 of 35 File: PGPB May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096827
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030096827 A1

TITLE: Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Yu, Guixue	Lawrenceville	NJ	US	
Macor, John	Guilford	CT	US	
Herpin, Timothy	Princeton	NJ	US	
Lawrence, R. Michael	Yardley	PA	US	
Morton, George C.	Collegeville	PA	US	
Ruel, Rejean	Saint-Lambert	CT	CA	
Poindexter, Graham S.	Old Saybrook		US	
Ruediger, Edward H.	Greenfield Park		CA	
Thibault, Carl	Mascouche		CA	

US-CL-CURRENT: 514/255.01; 514/330, 514/616, 544/386, 546/207, 546/226, 558/430, 558/445, 564/152

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

---

☐ 17. Document ID: US 20030092732 A1

L3: Entry 17 of 35 File: PGPB May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092732
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030092732 A1

TITLE: Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Yu, Guixue	Lawrenceville	NJ	US	
Macor, John	Guilford	CT	US	
Herpin, Timothy	Princeton	NJ	US	
Lawrence, R. Michael	Yardley	PA	US	
Morton, George C.	Collegeville	PA	US	
Ruel, Rejean	Saint-Lambert	CT	CA	
Poindexter, Graham S.	Old Saybrook		US	
Ruediger, Edward H.	Greenfield Park		CA	
Thibault, Carl	Mascouche		CA	

US-CL-CURRENT: 514/326; 514/330, 546/207, 546/226

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 18. Document ID: US 20030073626 A1

L3: Entry 18 of 35 File: PGPB Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030073626
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030073626 A1

TITLE: Compositions and methods for treating peripheral vascular disease

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hathaway, David R.	Lincoln	NE	US	
Coolidge, Thomas R.	Falls Village	CT	US	

US-CL-CURRENT: 514/12; 424/722, 424/94.4, 514/18, 514/23, 514/419, 514/458

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 19. Document ID: US 20030069169 A1

L3: Entry 19 of 35 File: PGPB Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030069169
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030069169 A1

TITLE: Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Macor, John E.	Guilford	CT	US	
Carlson, Kenneth E.	West Windsor	NJ	US	

US-CL-CURRENT: 514/2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

---

☐ 20. Document ID: US 20030040469 A1

L3: Entry 20 of 35 File: PGPB Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030040469
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030040469 A1

TITLE: Lowering serum lipids

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Knudsen, Liselotte Bjerre	Valby		DK	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

---

☐ 21. Document ID: US 20020143176 A1

L3: Entry 21 of 35 File: PGPB Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020143176
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020143176 A1

TITLE: Compounds derived from an amine nucleus and pharmaceutical compositions comprising same

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Liu, Chunjian	Pennington	NJ	US	
Dhar, T.G. Murali	Newtown	PA	US	
Gu, Henry H.	Bordentown	NJ	US	
Iwanowicz, Edwin J.	Cranbury	NJ	US	
Leftheris, Katerina	Skillman	NJ	US	
Pitts, William J.	Newtown	PA	US	
Herpin, Timothy F.	Princeton	NJ	US	
Pi, Zulan	Pennington	NJ	US	
Bisacchi, Gregory S.	Ringoes	NJ	US	

US-CL-CURRENT: 544/59; 544/162, 544/224, 544/336, 546/329, 548/556

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 22. Document ID: US 20020086861 A1

L3: Entry 22 of 35 File: PGPB Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086861
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020086861 A1

TITLE: Fused 1,2,4- thiadiazine derivatives, their preparation and use

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hansen, John Bondo	Jyderup		DK	
Nielsen, Flemming Elmelund	Virum		DK	

US-CL-CURRENT: 514/222.8; 544/10

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 23. Document ID: US 20020045616 A1

L3: Entry 23 of 35 File: PGPB Apr 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020045616
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020045616 A1

TITLE: Lactam inhibitors of FXa and method

PUBLICATION-DATE: April 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Stein, Philip D.	Pennington	NJ	US	
Shi, Yan	Flourtown	PA	US	
O'Connor, Stephen P.	Newtown	PA	US	
Li, Chi	Randolph	NJ	US	

US-CL-CURRENT: 514/212.08; 540/524

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

---

☐ 24. Document ID: US 20020025957 A1

L3: Entry 24 of 35 File: PGPB Feb 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020025957
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020025957 A1

TITLE: Lactam inhibitors of factor Xa and method

PUBLICATION-DATE: February 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Stein, Philip D.	Pennington	NJ	US	
O'Connor, Stephen P.	Newtown	PA	US	
Shi, Yan	Flourtown	PA	US	
Li, Chi	Randolph	NJ	US	

US-CL-CURRENT: 514/212.08; 514/319, 514/326, 514/422, 540/524, 546/207, 546/208, 548/517

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

---

☐ 25. Document ID: US 6713487 B2

L3: Entry 25 of 35 File: USPT Mar 30, 2004

US-PAT-NO: 6713487
DOCUMENT-IDENTIFIER: US 6713487 B2

TITLE: Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same

DATE-ISSUED: March 30, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guixue	Lawrenceville	NJ		
Macor; John	Guilford	CT		

Herpin; Timothy	Princeton	NJ	
Lawrence; R. Michael	Yardley	PA	
Morton; George C.	Collegeville	PA	
Ruel; Rejean	Saint-Lambert		CA
Poindexter; Graham S.	Old Saybrook	CT	
Ruediger; Edward H.	Greenfield Park		CA
Thibault; Carl	Mascouche		CA

US-CL-CURRENT: 514/278; 546/15, 546/17, 546/18

☐ 26. Document ID: US 6596747 B2

L3: Entry 26 of 35 File: USPT Jul 22, 2003

US-PAT-NO: 6596747
DOCUMENT-IDENTIFIER: US 6596747 B2

TITLE: Compounds derived from an amine nucleus and pharmaceutical compositions comprising same

DATE-ISSUED: July 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Liu; Chunjian	Pennington	NJ		
Dhar; T. G. Murali	Newtown	PA		
Gu; Henry H.	Bordentown	NJ		
Iwanowicz; Edwin J.	Cranbury	NJ		
Leftheris; Katerina	Skillman	NJ		
Pitts; William J.	Newtown	PA		
Herpin; Timothy F.	Princeton	NJ		
Bisacchi; Gregory S.	Ringoes	NJ		

US-CL-CURRENT: 514/374; 514/378, 548/215, 548/233, 548/240, 548/245

☐ 27. Document ID: US 6544981 B2

L3: Entry 27 of 35 File: USPT Apr 8, 2003

US-PAT-NO: 6544981
DOCUMENT-IDENTIFIER: US 6544981 B2

TITLE: Lactam inhibitors of factor Xa and method

DATE-ISSUED: April 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stein; Philip D.	Pennington	NJ		
O'Connor; Stephen P.	Newtown	PA		
Shi; Yan	Flourtown	PA		
Li; Chi	Randolph	NJ		

US-CL-CURRENT: 514/212.08; 540/526, 540/527

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

---

☐ 28. Document ID: US 6511973 B2

L3: Entry 28 of 35 File: USPT Jan 28, 2003

US-PAT-NO: 6511973
DOCUMENT-IDENTIFIER: US 6511973 B2

TITLE: Lactam inhibitors of FXa and method

DATE-ISSUED: January 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stein; Philip D.	Pennington	NJ		
Shi; Yan	Flourtown	PA		
O'Connor; Stephen P.	Newtown	PA		
Li; Chi	Randolph	NJ		

US-CL-CURRENT: 514/212.03; 514/212.08, 540/524, 540/527

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

---

☐ 29. Document ID: US 6329367 B1

L3: Entry 29 of 35 File: USPT Dec 11, 2001

US-PAT-NO: 6329367
DOCUMENT-IDENTIFIER: US 6329367 B1

TITLE: Fused 1,2,4-thiadiazine derivatives, their preparation and use

DATE-ISSUED: December 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hansen; John Bondo	Jyderup			DK
Nielsen; Flemming Elmelund	Virum			DK

US-CL-CURRENT: 514/222.8; 544/10

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc | Image

---

☐ 30. Document ID: US 6232310 B1

L3: Entry 30 of 35 File: USPT May 15, 2001

US-PAT-NO: 6232310
DOCUMENT-IDENTIFIER: US 6232310 B1

TITLE: Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use

DATE-ISSUED: May 15, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hansen; Holger Claus	V.ae butted.rl.o slashed.se			DK
Tagmose; Tina M.o slashed.ller	Ballerup			DK
Hansen; John Bondo	Jyderup			DK

US-CL-CURRENT: 514/224.2; 544/51, 544/52

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc | Image

---

☐ 31. Document ID: US 6100300 A

L3: Entry 31 of 35 File: USPT Aug 8, 2000

US-PAT-NO: 6100300
DOCUMENT-IDENTIFIER: US 6100300 A

TITLE: Metformin formulations and method for treating intermittent claudication employing same

DATE-ISSUED: August 8, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rogosky; Karen M.	Robbinsville	NJ		

US-CL-CURRENT: 514/635; 564/233

FILE 'HOME' ENTERED AT 12:05:13 ON 10 AUG 2004

=> file bioscience medicine dissabs
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'ADISCTI' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 12:05:29 ON 10 AUG 2004

FILE 'AQUALINE' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 12:05:29 ON 10 AUG 2004

FILE 'CAPLUS' ENTERED AT 12:05:29 ON 10 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 12:05:29 ON 10 AUG 2004

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 12:05:29 ON 10 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 12:05:29 ON 10 AUG 2004

FILE 'FOMAD' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 12:05:29 ON 10 AUG 2004

FILE 'HEALSAFE' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 12:05:29 ON 10 AUG 2004

FILE 'NIOSHTIC' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 12:05:29 ON 10 AUG 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 12:05:29 ON 10 AUG 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 12:05:29 ON 10 AUG 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 12:05:29 ON 10 AUG 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 12:05:29 ON 10 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:05:29 ON 10 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'IPA' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 American Society of Hospital Pharmacists (ASHP)

FILE 'NAPRALERT' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 12:05:29 ON 10 AUG 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

=> s (intermittent (w) claudication or (skeletal (w) muscle (w) injury (s) ischemia)) and (GLP-1 or glucagon (w) like (w) peptide (w) 1 or exendin?)

L1	0	FILE ADISCTI
L2	0	FILE ADISINSIGHT
L3	0	FILE ADISNEWS
L4	0	FILE AGRICOLA
L5	0	FILE AQUALINE
L6	0	FILE ANABSTR
L7	0	FILE ANTE
L8	0	FILE AQUASCI
L9	0	FILE BIOBUSINESS
L10	0	FILE BIOCOMMERCE
L11	0	FILE BIOENG
L12	0	FILE BIOSIS
L13	0	FILE BIOTECHDS
L14	0	FILE BIOTECHNO
L15	0	FILE CABA
L16	0	FILE CANCERLIT
L17	3	FILE CAPLUS
L18	0	FILE CEABA-VTB

```
L19             0 FILE CEN
L20             0 FILE CIN
L21             0 FILE CONFSCI
L22             0 FILE CROPB
L23             0 FILE CROPU
L24             0 FILE DISSABS
L25            25 FILE DGENE
L26             0 FILE DRUGB
L27             0 FILE DRUGMONOG2
L28             0 FILE IMSDRUGNEWS
L29             0 FILE DRUGU
L30             0 FILE IMSRESEARCH
L31             0 FILE EMBAL
L32             0 FILE EMBASE
L33             0 FILE ESBIOBASE
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'INJURY (S) ISCHEMIA'
L34             0 FILE FEDRIP
L35             0 FILE FOMAD
L36             0 FILE FOREGE
L37             0 FILE FROSTI
L38             0 FILE FSTA
L39             0 FILE GENBANK
L40             0 FILE HEALSAFE
L41             3 FILE IFIPAT
L42             0 FILE IMSPRODUCT
L43             0 FILE JICST-EPLUS
L44             0 FILE KOSMET
L45             0 FILE LIFESCI
L46             0 FILE MEDICONF
L47             0 FILE MEDLINE
L48             0 FILE NIOSHTIC
L49             0 FILE NTIS
L50             0 FILE NUTRACEUT
L51             0 FILE OCEAN
L52             0 FILE PASCAL
L53             0 FILE PCTGEN
L54             0 FILE PHAR
L55             0 FILE PHARMAML
L56             0 FILE PHIC
L57             0 FILE PHIN
L58             0 FILE PROMT
L59             0 FILE PROUSDDR
L60             0 FILE RDISCLOSURE
L61             0 FILE SCISEARCH
L62             0 FILE SYNTHLINE
L63             0 FILE TOXCENTER
L64            27 FILE USPATFULL
L65             4 FILE USPAT2
L66             0 FILE VETB
L67             0 FILE VETU
L68             0 FILE WATER
L69             4 FILE WPIDS
L70             0 FILE WPIFV
L71             0 FILE IPA
L72             0 FILE NAPRALERT
L73             2 FILE NLDB

TOTAL FOR ALL FILES
L74            68 (INTERMITTENT (W) CLAUDICATION OR (SKELETAL (W) MUSCLE (W) INJUR
                  Y (S) ISCHEMIA)) AND (GLP-1 OR GLUCAGON (W) LIKE (W) PEPTIDE
                  (W) 1 OR EXENDIN?)

=> dup rem l74
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
```

MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L74
L75 58 DUP REM L74 (10 DUPLICATES REMOVED)

=> d l75 1-58 ibib abs

L75 ANSWER 1 OF 58 COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2004:70053 NLDB
TITLE: Other News To Note.
SOURCE: BIOWORLD Today, (14 Apr 2004) Vol. 15, No. 71.
PUBLISHER: Thomson Healthcare, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1922

L75 ANSWER 2 OF 58 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:490736 CAPLUS
DOCUMENT NUMBER: 141:47336
TITLE: Combination treatment for diabetes and related diseases using **exendins** and thiazolidinediones
INVENTOR(S): Knudsen, Lotte Bjerre
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050115	A2	20040617	WO 2003-DK824	20031201

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:		
DK 2002-1864	A	20021203
US 2002-431999P	P	20021209

AB The invention provides methods for treatment and/or prevention of diabetes and diabetes-related diseases. More specifically, the methods and uses of the invention pertains to administration of an **exendin**-4 compound in combination with administration of a thiazolidinedione insulin sensitizer.

L75 ANSWER 3 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2004:108244 USPATFULL
TITLE: Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
INVENTOR(S): Rytved, Klaus Asger, Bagsvaerd, DENMARK
Dragsted, Nils, Stenlose, DENMARK
Nyborg, Niels Chresten Berg, Horsholm, DENMARK
Iversen, Lars, Hvidovre, DENMARK
Kristiansen, Marit, Soborg, DENMARK

NUMBER	KIND	DATE

PATENT INFORMATION: US 2004082646 A1 20040429
APPLICATION INFO.: US 2003-429626 A1 20030505 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2002-1630	20021028
	US 2002-422081P	20021029 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ, 08540
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
LINE COUNT: 1140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods which may effectively be used in the treatment and prevention of early cardiac and early cardiovascular diseases, for example of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, **intermittent claudication** (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 4 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2004:108239 USPATFULL
TITLE: Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
INVENTOR(S): Rytved, Klaus Asger, Bagsvaerd, DENMARK
Dragsted, Nils, Stenlose, DENMARK
Nyborg, Niels Chresten Berg, Horsholm, DENMARK
Iversen, Lars, Hvidovre, DENMARK
Kristiansen, Marit, Soborg, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004082641	A1	20040429
APPLICATION INFO.:	US 2003-429625	A1	20030505 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2002-1630	20021028
	US 2002-422081P	20021029 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ, 08540
NUMBER OF CLAIMS: 134
EXEMPLARY CLAIM: 1
LINE COUNT: 2267
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of treatment and prevention of early cardiac and early cardiovascular diseases, for instance of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, **intermittent claudication** (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration

of glycogen phosphorylase inhibitor compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 5 OF 58 USPATFULL on STN

ACCESSION NUMBER:	2004:101819 USPATFULL			
TITLE:	Abc expression promoters			
INVENTOR(S):	Sugiyama, Yasuo, Kawanishi-shi, JAPAN Fuse, Hiromatsu, Tsukuba-shi, JAPAN Hirakata, Masao, Kobe-shi, JAPAN Tozawa, Ryuichi, Toyonaka-shi, JAPAN			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004077689	A1	20040422	
APPLICATION INFO.:	US 2003-468433	A1	20031016	(10)
	WO 2002-JP4072		20020424	
	NUMBER		DATE	
PRIORITY INFORMATION:	JP 2001-128222		20010425	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069			
NUMBER OF CLAIMS:	43			
EXEMPLARY CLAIM:	1			
LINE COUNT:	3534			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The ABCA1 mRNA expression-promoting agent, LXRα mRNA expression-promoting agent, ABCG1 mRNA expression-promoting agent, cholesterol efflux-promoting agent, cholesteryl ester accumulation-inhibiting agent, ACAT-1 mRNA expression-inhibiting agent and CEH mRNA expression-promoting agent of the present invention are excellent in the ability to control cholesterol distribution in the body and have low toxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 6 OF 58 USPATFULL on STN

ACCESSION NUMBER:	2004:95419 USPATFULL			
TITLE:	N-substituted-2-oxodihydropyridine derivatives			
INVENTOR(S):	Sato, Nagaaki, Ibaraki, JAPAN Ando, Makoto, Ibaraki, JAPAN Ishikawa, Shiho, Ibaraki, JAPAN Nagase, Tsuyoshi, Ibaraki, JAPAN Nagai, Keita, Ibaraki, JAPAN Kanatani, Akio, Ibaraki, JAPAN			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004072874	A1	20040415	
APPLICATION INFO.:	US 2003-641017	A1	20030815	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	JP 2002-287015		20020930	
	JP 2002-353202		20021205	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021			
NUMBER OF CLAIMS:	45			
EXEMPLARY CLAIM:	1			
LINE COUNT:	4613			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula (I): ##STR1##

(wherein Ar.sup.1 and Ar.sup.2 are independently aryl or heteroaryl, any of which is optionally substituted by a substituent selected from the group consisting of cyano, halogen, nitro, lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, cyclo-lower alkyl, cyclo (lower alkyl)-lower alkyl, lower alkenyl, lower alkylamino, di-lower alkylamino, lower alkanoylamino, lower alkylsulfonylamino, arylsulfonylamino, hydroxy, lower alkoxy, halo-lower alkoxy, aryloxy, heteroaryloxy, lower alkylthio, carboxyl, formyl, lower alkanoyl, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, lower alkylsulfonyl, arylsulfonyl, aryl and heteroaryl;

R.sup.1and R.sup.2 are independently lower alkyl, cyclo-lower alkyl, cyclo(lower alkyl)-lower alkyl or lower alkoxy, any of which is optionally substituted by a substituent selected from the group consisting of halogen, lower alkylamino, di-lower alkylamino, lower alkanoylamino, hydroxy, lower alkoxy, formyl, lower alkoxycarbonyl, lower alkylcarbamoyl and di-lower alkylcarbamoyl;

R.sup.3, R.sup.4 and R.sup.5 are independently hydrogen, cyano, halogen or hydroxy, or lower alkyl, lower alkoxy or lower alkylthio, the last three groups being optionally substituted by a substituent selected from the group consisting of halogen, lower alkylamino, di-lower alkylamino, lower alkanoylamino, hydroxy, lower alkoxy, formyl, lower alkoxycarbonyl, lower alkylcarbamoyl and di-lower alkylcarbamoyl), or a salt or ester thereof is useful as a neuropeptide Y receptor antagonist agent and is also useful as an agent for the treatment of bulimia, obesity or diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 7 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2004:70949 USPATFULL
TITLE: Novel benzimidazole derivatives
INVENTOR(S): Otake, Norikazu, Tsukuba-shi, JAPAN
Moriya, Minoru, Tsukuba-shi, JAPAN
Ogino, Yoshio, Tsukuba-shi, JAPAN
Matsuda, Kenji, Tokyo, JAPAN
Nagae, Yoshikazu, Tsukuba-shi, JAPAN
Kanatani, Akio, Tsukuba-shi, JAPAN
Fukami, Takehiro, Tsukuba-shi, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004054177	A1	20040318	
APPLICATION INFO.:	US 2003-463390	A1	20030618	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2002-190978	20020628

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
LINE COUNT: 4107
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a compound of the formula (I): ##STR1##

(wherein A, B, C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or

optionally substituted methine; X is --N(SO.sub.2R.sup.4)--, --N(COR.sup.5)-- or --CO--; Y is --C(R.sup.6)(R.sup.7)--, --O-- or --N(R.sup.8)--, provided that the compound (I) when E is nitrogen, n is 0, X is --CO--, and Y is --O-- is excluded) and the like, which are useful as an agent for the treatment of various diseases related to NPY, for example cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, hyperlipidemia, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorder, inflammatory diseases or glaucoma, and the like, also for example, atherosclerosis, hypogonadism, hyperandrogenism, polycystic ovary syndrome (Pickwickian syndrome), hirsutism, gastro-intestinal motility disorder, obesity-related gastro-esophageal reflux, obesity hypoventilation, sleep apnea, inflammation, systemic inflammation of the vasculature, osteoarthritis, insulin resistance, bronchoconstriction, alcohol preference, metabolic syndrome, Alzheimer's disease, cardiac hypertrophy, left ventricular hypertrophy, hypertriglyceridemia, low HDL cholesterol, cardiovascular disorders such as coronary heart disease (CHD), cerebrovascular disease, stroke, peripheral vascular disease, sudden death, gallbladder diseases, cancer (breast, endometrial, colon), breathlessness, hyperuricemia, impaired fertility, low back pain, or increased anesthetic risk, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 8 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2004:70661 USPATFULL
TITLE: Pharmaceutical use of boronic acids and esters thereof
INVENTOR(S): Ebdrup, Soren, Roskilde, DENMARK
Vedso, Per, Frederiksberg, DENMARK
Jacobsen, Poul, Slangerup, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004053889	A1	20040318
APPLICATION INFO.:	US 2003-614233	A1	20030707 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2003-DK315, filed on 14 May 2003, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2002-902	20020614

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Reza Green, Esq, Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ, 08540
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 2139
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Use of compounds to inhibit hormone-sensitive lipase, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, method of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of a range of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 9 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2004:51602 USPATFULL
TITLE: (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
INVENTOR(S): Atwal, Karnail S., Pennington, NJ, UNITED STATES
Grover, Gary J., Stockton, NJ, UNITED STATES
Ding, Charles Z., Dallas, TX, UNITED STATES
Stein, Philip D., Pennington, NJ, UNITED STATES
Lloyd, John, Yardley, PA, UNITED STATES
Ahmad, Saleem, Wall, NJ, UNITED STATES
Hamann, Lawrence G., Cherry Hill, NJ, UNITED STATES
Green, David, Haverhill, MA, UNITED STATES
Ferrara, Francis N., Bedminster, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004039033	A1	20040226	
APPLICATION INFO.:	US 2002-315818	A1	20021210	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-339108P	20011210 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 2858
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), and pharmaceutically acceptable salts thereof, ##STR1##

are useful for modulating mitochondrial F.sub.1F.sub.0 ATPase activity and treating ischemic conditions including myocardial infarction, congestive heart failure, and cardiac arrhythmias.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 10 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2004:13450 USPATFULL
TITLE: Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
INVENTOR(S): Ding, Charles Z., Plano, TX, UNITED STATES
Hamann, Lawrence G., Cherry Hill, NJ, UNITED STATES
Stein, Philip D., Pennington, NJ, UNITED STATES
Pudzianowski, Andrew T., Yardley, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009972	A1	20040115	
APPLICATION INFO.:	US 2003-461736	A1	20030613	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-389213P	20020617 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 1625
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), ##STR1##

are useful as inhibitors of mitochondrial F.sub.1F.sub.0 ATP hydrolase, wherein R.sub.1, R.sub.5 and R.sub.7 are optional substituents, R.sub.2, R.sub.3 and R.sub.4 are hydrogen, alkyl, or substituted alkyl, or comprise a bond to R, T or Y; Z and Y are selected from C(.dbd.O), --CO.sub.2--, --SO.sub.2--, --CH.sub.2--, --CH.sub.2C(.dbd.O)--, and --C(.dbd.O)C(.dbd.O)--, or Z may be absent; R and T are CH.sub.2--, --C(.dbd.O)--, or --CH[(CH.sub.2).sub.p(Q)]--, wherein Q is NR.sub.10R.sub.11, OR.sub.10 or CN and p is 0, 1 or 2; R.sub.6 is alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, cycloalkyl, heterocyclo, or heteroaryl; R.sub.10 and R.sub.11 are hydrogen, alkyl, or substituted alkyl; and r and t are 0 or 1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 11 OF 58 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2003:551365 CAPLUS
DOCUMENT NUMBER: 139:111703
TITLE: Method and composition using a dipeptidyl peptidase IV inhibitor-neutral endopeptidase inhibitor combination for treatment of diabetes, hypertension, chronic heart failure, and fluid retentive states
INVENTOR(S): Carr, Richard David
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057200	A2	20030717	WO 2003-DK17	20030113
WO 2003057200	A3	20040624		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003236272	A1	20031225	US 2003-421465	20030423
PRIORITY APPLN. INFO.:			DK 2002-47	A 20020111
			US 2002-348332P	P 20020114
			WO 2003-DK17	A1 20030113

OTHER SOURCE(S): MARPAT 139:111703

AB The invention provides a method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states, comprising administering inhibitors of neutral endopeptidase and dipeptidyl peptidase IV (DPP-IV) to individuals suffering from one or more of these conditions. Inhibition of the activity of the two enzymes will potentiate the insulin-releasing activity of endogenous **glucagon-like peptide 1** (**GLP-1**) and other DPP-IV substrates, e.g. gastric inhibitory peptide (GIP). Preparation of heterocyclic DPP-IV inhibitors is described.

L75 ANSWER 12 OF 58 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2003:300601 CAPLUS
DOCUMENT NUMBER: 138:298126
TITLE: Compositions and methods for treating peripheral vascular disease with **GLP-1** compounds

INVENTOR(S): Hathaway, David R.; Coolidge, Thomas R.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S. Ser. No. 851,738.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003073626	A1	20030417	US 2002-91258		20020305
US 6284725	B1	20010904	US 1999-302596		19990430
US 2002055460	A1	20020509	US 2001-851738		20010509
PRIORITY APPLN. INFO.:			US 1999-302596	A3	19990430
			US 2001-851738	A2	20010509
			US 1998-103498P	P	19981008

AB The present invention relates to methods of treating **intermittent claudication** comprising administering **glucagon-like peptide-1** (**GLP-1**) mols. to subjects suffering therefrom. A method of treating or preventing **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a subject comprising the step of administering a therapeutically effective amount of **GLP-1** mol. is also claimed. The subject can also be administered free radical scavengers, glucose, or potassium. The **GLP-1** compound is administered by an infusion pump or by s.c. injection of a slow-release formulation.

L75 ANSWER 13 OF 58 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 3
AN 10491841 IFIPAT;IFIUDB;IFICDB
TITLE: METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES
INVENTOR(S): Carr; Richard David, Vaerlose, DK
PATENT ASSIGNEE(S): Unassigned
AGENT: Reza Green, Esq. Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ, 08540, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2003236272	A1	20031225
APPLICATION INFORMATION:	US 2003-421465		20030423

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
CONTINUATION OF:	WO 2003-DK17	20030113	

	NUMBER	DATE	
PRIORITY APPLN. INFO.:	DK 2002-47	20020111	
	US 2002-348332P	20020114	(Provisional)
FAMILY INFORMATION:	US 2003236272	20031225	

DOCUMENT TYPE: Utility
Patent Application - First Publication
FILE SEGMENT: CHEMICAL
APPLICATION

PARENT CASE DATA:

This application is a continuation of application serial no. PCT/ DK03/00017 filed on Jan. 13, 2003 and claims priority under 35 U.S.C. 119 of Danish application no. PA 2002 00047 filed Jan. 11, 2002 and U.S. provisional application No. 60/348,332 filed Jan. 14, 2002, the contents of which are fully

incorporated herein by reference.

NUMBER OF CLAIMS: 23

AB The present invention is related to a method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states comprising administering inhibitors of the enzymes NEP and DPP-IV to individuals suffering from one or more of those conditions. Inhibition of the activity of the two enzymes will potentiate the insulin releasing activity of endogenous **GLP-1** and other DPP-IV substrates like GIP.

CLMN 23

L75 ANSWER 14 OF 58 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 4

AN 10475826 IFIPAT;IFIUDB;IFICDB

TITLE: **GLP-1** AGONIST AND CARDIOVASCULAR COMPLICATIONS

INVENTOR(S): Carr; Richard David, Vaerlose, DK
Christoffersen; Christina, Kobenhavn, DK
Elbrond; Bodil, Kobenhavn, DK
Knudsen; Liselotte Bjerre, Valby, DK
Larsen; Jens, Fredensborg, DK
Nielsen; Lars Bo, Virum, DK
Rolin; Bidda Charlotte, Naerum, DK
Selmer; Johan, Farum, DK

PATENT ASSIGNEE(S): Unassigned

AGENT: Reza Green, Esq. Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ, 08540, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2003220255	A1	20031127
APPLICATION INFORMATION:	US 2003-406426		20030403

	NUMBER	DATE
PRIORITY APPLN. INFO.:	DK 2002-499	20020404
	US 2002-375255P	20020423 (Provisional)
FAMILY INFORMATION:	US 2003220255	20031127

DOCUMENT TYPE: Utility
Patent Application - First Publication

FILE SEGMENT: CHEMICAL
APPLICATION

PARENT CASE DATA:

This application claims priority under 35 U.S.C. 119 of Danish application no. PA 2002 00499 filed Apr. 4, 2002, and to U.S. provisional application No. 60/375255 filed Apr. 23, 2002, the contents of which are fully incorporated herein by reference.

NUMBER OF CLAIMS: 90

AB Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a **GLP-1** agonist.

CLMN 90

L75 ANSWER 15 OF 58 USPATFULL on STN DUPLICATE 5

ACCESSION NUMBER: 2003:140985 USPATFULL

TITLE: Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same

INVENTOR(S): Yu, Guixue, Lawrenceville, NJ, UNITED STATES
Macor, John, Guilford, CT, UNITED STATES
Herpin, Timothy, Princeton, NJ, UNITED STATES
Lawrence, R. Michael, Yardley, PA, UNITED STATES
Morton, George C., Collegeville, PA, UNITED STATES

Ruel, Rejean, Saint-Lambert, CANADA
Poindexter, Graham S., Old Saybrook, CT, UNITED STATES
Ruediger, Edward H., Greenfield Park, CANADA
Thibault, Carl, Mascouche, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003096827	A1	20030522	
	US 6713487	B2	20040330	
APPLICATION INFO.:	US 2002-90288	A1	20020304	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-273206P	20010302	(60)
	US 2001-273291P	20010302	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 2509
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), ##STR1##

NR.sub.11R.sub.12; G is a novel side chain selected from C.sub.2-6alkenyl, A.sub.3-aryl, --OR.sub.18, heteroaryl, A.sub.1-cyano, A.sub.2--OR.sub.17, A.sub.1--C(.dbd.O)R.sub.18, A.sub.1--CO.sub.2R.sub.18, A.sub.1--C(.dbd.O)NR.sub.18R.sub.19, A.sub.1--OC(.dbd.O)R.sub.18, A.sub.1--NR.sub.18C(.dbd.O)R.sub.19, A.sub.1--OC(.dbd.O)NR.sub.18R.sub.19, A.sub.1--NR.sub.18CO.sub.2R.sub.19, A.sub.1--NR.sub.18SO.sub.2R.sub.17, A.sub.1--SO.sub.2R.sub.17, A.sub.1--NR.sub.20C(.dbd.O)NR.sub.18R.sub.19, and A.sub.1--SR.sub.18; or when y is 0 or when W is not NHR.sub.22, G may be A.sub.1-heterocyclo, wherein A.sub.1 is a bond, C.sub.1-6alkylene or C.sub.2-alkenylene, A.sub.2 is C.sub.1-6alkylene or C.sub.2-6alkenylene, and A.sub.3 is C.sub.2-6alkenylene; W is selected from --NR.sub.21R.sub.22, --OR.sub.23, --NR.sub.21C(.dbd.O)R.sub.24, --NR.sub.21CO.sub.2R.sub.24, amidino, guanidino, or a heteroaryl, heterocyclo or C.sub.3-7cycloalkyl as defined in the specification, and X and R.sub.1 through R.sub.24 are as defined in the specification, are effective as modulators of melanocortin-receptors, particularly MC-1R and MC-4R.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 16 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2003:318756 USPATFULL
TITLE: Bone morphogenic protein polynucleotides, polypeptides, and antibodies
INVENTOR(S): Young, Paul E., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003224501	A1	20031204	
APPLICATION INFO.:	US 2003-366345	A1	20030214	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-345236, filed on 16 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2001-809269, filed on 16 Mar 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US9229, filed on 23 Mar 2001, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-356749P	20020215	(60)

	US 2000-190067P	20000317	(60)
	US 2002-348621P	20020117	(60)
	US 2002-349356P	20020122	(60)
	US 2002-351520P	20020128	(60)
	US 2002-354265P	20020206	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 16963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human BMP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human BMP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human BMP polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 17 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2003:306402 USPATFULL
TITLE: Bone morphogenic protein polynucleotides, polypeptides, and antibodies
INVENTOR(S): Young, Paul E., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

PATENT INFORMATION:	NUMBER	KIND	DATE	
	US 2003215836	A1	20031120	
APPLICATION INFO.:	US 2003-345236	A1	20030116	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-809269, filed on 16 Mar 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US9229, filed on 23 Mar 2001, PENDING

PRIORITY INFORMATION:	NUMBER	DATE	
	US 2000-190067P	20000317	(60)
	US 2002-348621P	20020117	(60)
	US 2002-349356P	20020122	(60)
	US 2002-351520P	20020128	(60)
	US 2002-354265P	20020206	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 17572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human BMP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human BMP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human BMP polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 18 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:238532 USPATFULL
TITLE: Use of compounds for decreasing activity of hormone-sensitive
INVENTOR(S): Ebdrup, Soren, Roskilde, DENMARK
de Jong, Johannes Cornelis, Bagsvaerd, NETHERLANDS
Jacobsen, Poul, Slangerup, DENMARK
Hansen, Holger Claus, Vaerlose, DENMARK
Vedso, Per, Frederiksberg, DENMARK

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003166690	A1	20030904	
APPLICATION INFO.:	US 2002-319212	A1	20021213	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	DK 2001-1879	20011214	
	DK 2002-645	20020430	
	DK 2002-1000	20020627	
	DK 2002-1562	20021011	
	US 2002-346909P	20020103	(60)
	US 2002-384243P	20020530	(60)
	US 2002-393068P	20020628	(60)
	US 2002-418481P	20021015	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ, 08540
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
LINE COUNT: 15810
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 19 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2003:238486 USPATFULL
TITLE: Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
INVENTOR(S): Ebdrup, Soren, Roskilde, DENMARK
de Jong, Johannes Cornelis, Bagsvaerd, DENMARK
Jacobsen, Poul, Slangerup, DENMARK
Hansen, Holger Claus, Vaerlose, DENMARK
Vedso, Per, Frederiksberg, DENMARK

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003166644	A1	20030904	
APPLICATION INFO.:	US 2002-319885	A1	20021213	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	DK 2001-1879	20011214	
	DK 2002-645	20020430	
	DK 2002-1000	20020627	
	DK 2002-1562	20021011	
	US 2002-346909P	20020103	(60)
	US 2002-384243P	20020530	(60)
	US 2002-393068P	20020628	(60)
	US 2002-418481P	20021015	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ, 08540
NUMBER OF CLAIMS: 327
EXEMPLARY CLAIM: 1
LINE COUNT: 20859
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 20 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2003:200810 USPATFULL
TITLE: Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, BGS-8, expressed highly in immune tissue
INVENTOR(S): Wu, Shujian, Langhorne, PA, UNITED STATES
Lee, Liana M., North Brunswick, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003138795	A1	20030724	
APPLICATION INFO.:	US 2002-173461	A1	20020614	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-298340P	20010614 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 13042
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding BGS-8 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-8 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 21 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2003:134643 USPATFULL
TITLE: Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
INVENTOR(S): Yu, Guixue, Lawrenceville, NJ, UNITED STATES
Macor, John, Guilford, CT, UNITED STATES
Herpin, Timothy, Princeton, NJ, UNITED STATES
Lawrence, R. Michael, Yardley, PA, UNITED STATES
Morton, George C., Collegeville, PA, UNITED STATES

Ruel, Rejean, Saint-Lambert, CANADA
Poindexter, Graham S., Old Saybrook, CT, UNITED STATES
Ruediger, Edward H., Greenfield Park, CANADA
Thibault, Carl, Mascouche, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003092732	A1	20030515	
APPLICATION INFO.:	US 2002-90582	A1	20020304	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-273206P	20010302	(60)
	US 2001-273291P	20010302	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 2878
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates and prodrugs thereof, ##STR1##

in which E is

X is N or CH, W is --NR.sub.16R.sub.17, --NR.sub.16C(.dbd.O)R.sub.22, --NR.sub.16CO.sub.2R.sub.22, --OR.sub.23, or a heteroaryl or heterocyclo group as defined in the specification, and R.sub.1 through R.sub.12, R.sub.16, R.sub.17, R.sub.22, R.sub.23, x, y, and z are as defined in the specification, are useful as modulaters of melanocortin receptors, particularly MC-1R and MC-4R.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 22 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2003:100059 USPATFULL
TITLE: Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
INVENTOR(S): Macor, John E., Guilford, CT, UNITED STATES
Carlson, Kenneth E., West Windsor, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003069169	A1	20030410	
APPLICATION INFO.:	US 2002-90258	A1	20020304	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-273206P	20010302	(60)
	US 2001-273291P	20010302	(60)
	US 2001-289719P	20010509	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2497
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Co-administration of a melanocortin receptor agonist, particularly an MC-1R or MC-4R agonist, and a cAMP phosphodiesterase inhibitor is described for modulating levels of cyclic adenoise 3',5' monophosphate

(cAMP) in a mammal. The inventive co-administration is useful in the treatment of diseases affected by activity of cAMP-PDE, including without limitation, inflammatory bowel disease, irritable bowel syndrome, rheumatoid arthritis, osteoarthritis, pancreatis, psoriasis, migraine, Alzheimer's Disease, Parkinson's disease, transplant rejection, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, stroke, and neurodegeneration of, and consequences of traumatic brain injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 23 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2003:57903 USPATFULL
TITLE: Lowering serum lipids
INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003040469	A1	20030227	
APPLICATION INFO.:	US 2001-800541	A1	20010307	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-375	20000308
	US 2000-191593P	20000320 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6400
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 2265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for lowering serum lipids in a patient by administering a **GLP-1** agonist. The invention is useful for treating diseases that may be alleviated by lowering serum lipid levels, including, e.g., cardiovascular disease and diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 24 OF 58 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: 2004-022543 [02] WPIDS
DOC. NO. CPI: C2004-007005
TITLE: Use of a **glucagon like peptide-1** agonist or its salt for the preparation of a pharmaceutical composition for the treatment or prevention of an early cardiac or early cardiovascular disease in a diabetic or non-diabetic patient.
DERWENT CLASS: B04
INVENTOR(S): CARR, R D; CHRISTOFFERSEN, C; ELBROND, B; KNUDSEN, L B; LARSEN, J; NIELSEN, L B; ROLIN, B C; SELMER, J
PATENT ASSIGNEE(S): (CARR-I) CARR R D; (CHRI-I) CHRISTOFFERSEN C; (ELBR-I) ELBROND B; (KNUD-I) KNUDSEN L B; (LARS-I) LARSEN J; (NIEL-I) NIELSEN L B; (ROLI-I) ROLIN B C; (SELM-I) SELMER J; (NOVO) NOVO NORDISK AS
COUNTRY COUNT: 103
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003084563	A1	20031016	(200402)*	EN	14
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL
PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA
ZM ZW

US 2003220255 A1 20031127 (200402)
AU 2003226913 A1 20031020 (200436)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003084563	A1	WO 2003-DK216	20030402
US 2003220255	A1 Provisional	US 2002-375255P	20020423
		US 2003-406426	20030403
AU 2003226913	A1	AU 2003-226913	20030402

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003226913	A1 Based on	WO 2003084563

PRIORITY APPLN. INFO: US 2002-375255P 20020423; DK 2002-499 20020404; US 2003-406426 20030403

AN 2004-022543 [02] WPIDS

AB WO2003084563 A UPAB: 20040107

NOVELTY - In the treatment or prevention of an early cardiac or early cardiovascular disease in a diabetic or non-diabetic patient a **glucagon like peptide-1** (GLP1) agonist or its salt is used.

ACTIVITY - Cardiant; Cardiovascular-Gen.; Antiarrhythmic; Antianginal; Antiarteriosclerotic; Vasotropic; Hypotensive.

MECHANISM OF ACTION - Glucose metabolism regulator; Cardiovascular hemodynamics regulator; Brain natriuretic peptide (BNP) in plasma and/or heart tissue inhibitor. Hearts from 12 streptozotocin (STZ)-treated pigs were collected. The pigs were treated with STZ 2 weeks prior to dosing with either the **GLP-1** derivative, Arg34, Lys26(N- eta (gamma -Glu(N- alpha -hexadecanoyl)))-**GLP-1**(7-37) (NN2211) for 4 weeks, at a dose of 3.3 micro g/kg, subcutaneously once daily or with a vehicle. STZ-treated pigs were either hyperglycemic or glucose intolerant and had impaired insulin secretion upon oral glucose tolerance tests. BNP mRNA and protein levels in cardiac biopsies were measured with real-time PCR and RIA assays, respectively. BNP mRNA levels were normalized by beta -actin mRNA levels. BNP mRNA levels were similar in right atrial (RA), left atrial (LA) and in left ventricular (LV) biopsies from vehicle treated diabetic pigs (-GLP). However, in hearts from NN2211 (+GLP) treated pigs the levels of BNP were significantly lower than in vehicle treated pigs. The BNP mRNAs (arb.units) in the RA, LA and LV in the NN2211/vehicle treated pigs was found to be 0.13/1.3, 0.37/1.5 and 0.75/1.15, respectively.

USE - For the treatment or prevention of an early cardiac or early cardiovascular disease (e.g. left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, atherosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, **intermittent claudication** (e.g. atherosclerosis obliterens), diastolic dysfunction and systolic dysfunction) in a diabetic or non-diabetic patient; for the preparation of a pharmaceutical composition for reducing the level of brain natriuretic peptide (BNP) in plasma and/or heart tissue in a diabetic or non-diabetic patient (all claimed). Also useful for the treatment of myocardial infarction, acute coronary syndrome, unstable angina, non-Q-wave cardiac necrosis, Q-wave myocardial infarct and morbidity after stroke.

ADVANTAGE - The **GLP-1** agonists are in the form of stable derivatives and exhibit a protracted profile of action compared to the corresponding other **GLP-1** analogs. The **GLP-1** analogs lower the brain natriuretic peptide (BNP) in the plasma and/or heart tissue, in addition to lowering blood glucose and plasma lipids.
Dwg.0/1

L75 ANSWER 25 OF 58 COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2002:241031 NLDB
TITLE: OTHER NEWS TO NOTE.
SOURCE: BIOWORLD Today, (26 Sep 2002) Vol. 13, No. 185.
PUBLISHER: Medical Economics/Thomson Healthcare
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 2214

L75 ANSWER 26 OF 58 USPATFULL on STN DUPLICATE 6
ACCESSION NUMBER: 2002:259599 USPATFULL
TITLE: Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
INVENTOR(S): Liu, Chunjian, Pennington, NJ, UNITED STATES
Dhar, T.G. Murali, Newtown, PA, UNITED STATES
Gu, Henry H., Bordentown, NJ, UNITED STATES
Iwanowicz, Edwin J., Cranbury, NJ, UNITED STATES
Leftheris, Katerina, Skillman, NJ, UNITED STATES
Pitts, William J., Newtown, PA, UNITED STATES
Herpin, Timothy F., Princeton, NJ, UNITED STATES
Pi, Zulan, Pennington, NJ, UNITED STATES
Bisacchi, Gregory S., Ringoes, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002143176	A1	20021003
	US 6596747	B2	20030722
APPLICATION INFO.:	US 2001-997963	A1	20011129 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-428432, filed on 27 Oct 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106186P	19981029 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 2608
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), ##STR1##

are effective as inhibitors of IMPDH enzyme and/or serine protease Factor VIIa, wherein B is a monocyclic or bicyclic carbocyclic or heterocyclic ring, D is a monocyclic or bicyclic carbocyclic or heterocyclic ring except when A is a heterocyclic ring, then D is a heterocyclic ring system, R is hydrogen or C.sub.1-4alkyl, and A, R.sub.1, R.sub.2 and R.sub.4 are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 27 OF 58 USPATFULL on STN DUPLICATE 7
ACCESSION NUMBER: 2002:85574 USPATFULL
TITLE: Lactam inhibitors of FXa and method
INVENTOR(S): Stein, Philip D., Pennington, NJ, UNITED STATES

Shi, Yan, Flourtown, PA, UNITED STATES
O'Connor, Stephen P., Newtown, PA, UNITED STATES
Li, Chi, Randolph, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002045616	A1	20020418	
	US 6511973	B2	20030128	
APPLICATION INFO.:	US 2001-916941	A1	20010727	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-222498P	20000802	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 1116
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compound of the formula ##STR1##

are inhibitors of the enzyme Factor Xa. These compounds are useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 28 OF 58 USPATFULL on STN DUPLICATE 8
ACCESSION NUMBER: 2002:43590 USPATFULL
TITLE: Lactam inhibitors of factor Xa and method
INVENTOR(S): Stein, Philip D., Pennington, NJ, UNITED STATES
O'Connor, Stephen P., Newtown, PA, UNITED STATES
Shi, Yan, Flourtown, PA, UNITED STATES
Li, Chi, Randolph, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002025957	A1	20020228	
	US 6544981	B2	20030408	
APPLICATION INFO.:	US 2001-874739	A1	20010605	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-210384P	20000609	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 2820
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Lactam inhibitors are provided which have the structure ##STR1##

including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrug esters thereof, wherein n is 1 to 5; and

and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 , R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.10a, 10.sub.11 and R.sub.12 are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 29 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2002:165232 USPATFULL
TITLE: Fused 1,2,4- thiadiazine derivatives, their preparation and use
INVENTOR(S): Hansen, John Bondo, Jyderup, DENMARK
Nielsen, Flemming Elmelund, Virum, DENMARK

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002086861	A1	20020704	
APPLICATION INFO.:	US 2001-12145	A1	20011207	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-464979, filed on 16 Dec 1999, PATENTED

PRIORITY INFORMATION:	NUMBER	DATE
	DK 1998-1693	19981218
	DK 1999-18	19990111
	US 1999-115544P	19990112 (60)
	US 1999-116438P	19990120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Reza Green, Esq., Nova Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
LINE COUNT: 1153
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to 4H-thieno[3,2-e]-1,2,4-thiadiazine derivatives of the general formula: ##STR1##

wherein X, Y, R.sup.1, R.sup.2 and R.sup.3 are defined in the description, compositions thereof and methods for preparing the compounds are described.

The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 30 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2001:226624 USPATFULL
TITLE: Fused 1,2,4-thiadiazine derivatives, their preparation and use
INVENTOR(S): Hansen, John Bondo, Jyderup, Denmark
Nielsen, Flemming Elmelund, Virum, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6329367	B1	20011211	
APPLICATION INFO.:	US 1999-464979		19991216	(9)

PRIORITY INFORMATION:	NUMBER	DATE
	DK 1998-1693	19981218
	DK 1999-18	19990111
	US 1999-115544P	19990112 (60)
	US 1999-116438P	19990120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Truong, Tamthom N.
LEGAL REPRESENTATIVE: Green, Esq., Reza, Agris, Esq., Cheryl H.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 1111
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to 4H-thieno[3,2-e]-1,2,4-thiadiazine derivatives of the general formula: ##STR1##

wherein X, Y, R.sup.1, R.sup.2 and R.sup.3 are defined in the description, compositions thereof and methods for preparing the compounds are described.

The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 31 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2001:71545 USPATFULL
TITLE: Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
INVENTOR(S): Hansen, Holger Claus, V.ae butted.rl.o slashed.se, Denmark
Tagmose, Tina M.o slashed.ller, Ballerup, Denmark
Hansen, John Bondo, Jyderup, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6232310	B1	20010515	
APPLICATION INFO.:	US 2000-520447		20000308	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	DK 1999-353	19990312	
	US 1999-125883P	19990324	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: McKenzie, Thomas
LEGAL REPRESENTATIVE: Zelson, Esq., Steve T., Rozek, Esq., Carol E.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1463
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to fused 1,4-thiazine-2-carbonitrile derivatives, compositions thereof and methods for preparing the compounds.

The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 32 OF 58 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: 2001-602602 [68] WPIDS
CROSS REFERENCE: 2002-707076 [76]
DOC. NO. CPI: C2001-178492
TITLE: Use of **glucagon-like peptide -1** agonist for manufacturing a medicament for lowering total serum lipids e.g. low density lipoproteins

and cholesterol.

DERWENT CLASS: B04
INVENTOR(S): KNUDSEN, L B; LARSEN, P J; SELMER, J; STURIS, J
PATENT ASSIGNEE(S): (NOVO) NOVO NORDISK AS
COUNTRY COUNT: 94
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001066135	A1	20010913	(200168)*	EN	52
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
AU 2001037254	A	20010917	(200204)		
EP 1263458	A1	20021211	(200301)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
JP 2003525908	W	20030902	(200358)		71

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001066135	A1	WO 2001-DK150	20010308
AU 2001037254	A	AU 2001-37254	20010308
EP 1263458	A1	EP 2001-909571	20010308
		WO 2001-DK150	20010308
JP 2003525908	W	JP 2001-564787	20010308
		WO 2001-DK150	20010308

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2001037254	A	Based on	WO 2001066135
EP 1263458	A1	Based on	WO 2001066135
JP 2003525908	W	Based on	WO 2001066135

PRIORITY APPLN. INFO: DK 2000-375 20000308
AN 2001-602602 [68] WPIDS
CR 2002-707076 [76]
AB WO 200166135 A UPAB: 20030910
NOVELTY - A medicament for lowering total serum lipids comprise glucagon-like peptide (**GLP**)-**1** agonist.

ACTIVITY - Antilipemic; Cardiant; Cerebroprotective; Antidiabetic; Antiarteriosclerotic; Vasotropic; Nootropic; Antianginal; Anorectic.

Acute and subchronic anorectic effects of Arg34,Lys26(N approx. e-(approx. c-Glu(N approx. a-hexadecanoyl)))-**GLP-1**(7 - 23)(**GLP-1**) were studied in both normal Wistar rats and a model of hypothalamic obesity (Wistar rats subjected to neonatal monosodium glutamate treatment (MSG)). MSG lesioned rats were randomly assigned to groups receiving **GLP-1** or vehicle. **GLP-1** (100 mg/kg) was administered by subcutaneous injection twice daily. **GLP-1** was dissolved in sterile phosphate buffered saline (50 mM, pH 7.4) to a final concentration of either 0.1 or 1 mg/ml. An inhibition of food intake was observed, accompanied by reduced body weight, initial decreases in water intake and increases in diuresis were normalized within few days of treatment, and plasma parameters of renal function remained normal throughout the experiment. Lowered plasma levels of triglycerides were observed. In normal rats from 1.58 plus or minus 0.1 - 1.21 plus or minus 0.3 mM and in MSG rats 2.27 plus or minus 0.3 - 1.49 plus or minus 0.1 mM.

MECHANISM OF ACTION - **GLP-1** agonist.

USE - For manufacturing a medicament for lowering total serum lipids, such as low density lipoproteins (LDL); particularly small, dense LDL, very low density lipoproteins (VLDL); triglycerides, cholesterol, LDL/HDL ratio and non-esterified fatty acid, for increasing high density lipoproteins (HDL), lowering plasma levels of lipoprotein (Lp(a)), inhibiting generation of apolipoprotein (a) (apo(a)); for treating dyslipidemia in humans (all claimed) and also for lowering fatty acids, such as free fatty acids and non-esterified fatty acids (all claimed). The medicament is also useful for treating a condition such as cardiovascular diseases, stroke, cerebral hemorrhage, coronary heart disease, coronary artery disease, diabetic vasculopathy, atherosclerosis, peripheral atherosclerosis, arteriosclerosis, myocardial infarction, restenosis, peripheral artery disease, **intermittent claudication**, aneurisms of aorta and other large arteries, by pass graft stenosis, diabetes mellitus (type I and II), hyperglycemia and for an anticoagulative treatment e.g. following a coronary thrombosis or after surgery.

ADVANTAGE - **GLP-1** show a long-term effect in lowering levels of plasma lipids such as triglycerides, cholesterol and non-esterified fatty acids.

Dwg.0/0

L75 ANSWER 33 OF 58 USPATFULL on STN

ACCESSION NUMBER:	2000:102332 USPATFULL
TITLE:	Metformin formulations and method for treating **intermittent claudication** employing same
INVENTOR(S):	Rogosky, Karen M., Robbinsville, NJ, United States
PATENT ASSIGNEE(S):	Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6100300		20000808	
APPLICATION INFO.:	US 1998-67565		19980428	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Fonda, Kathleen K.			
LEGAL REPRESENTATIVE:	Rodney, Burton			
NUMBER OF CLAIMS:	6			
EXEMPLARY CLAIM:	1			
LINE COUNT:	331			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel metformin formulations are provided which include metformin or metformin salts preferably the hydrochloride salt in doses below that employed for treating diabetes such as metformin in daily amounts of 400 mg or below. A method for treating peripheral vascular disease including **intermittent claudication** employing such metformin formulations is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L75 ANSWER 34 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

ACCESSION NUMBER:	ADH73030 peptide DGENE
TITLE:	Use of a **glucagon like peptide-1** agonist or its salt for the preparation of a pharmaceutical composition for the treatment or prevention of an early cardiac or early cardiovascular disease in a diabetic or non- diabetic patient.
INVENTOR:	Knudsen L B; Rolin B C; Carr R D; Selmer J; Larsen J; Elbrond B; Nielsen L B; Christoffersen C
PATENT ASSIGNEE:	(NOVO)NOVO NORDISK AS.
PATENT INFO:	WO 2003084563 A1 20031016 14p
APPLICATION INFO:	WO 2003-DK216 20030402
PRIORITY INFO:	DK 2002-499 20020404
	US 2002-375255P 20020423

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2004-022543 [02]
DESCRIPTION: **Glucagon like peptide-1** related **exendin** peptide 2.

AN ADH73030 peptide DGENE

AB This invention relates to a novel method for the treatment or prevention of an early cardiac or early cardiovascular disease in a diabetic or non-diabetic patient where a **glucagon like peptide-1** (**GLP 1**) agonist or its salt is used. The invention may be useful for the development of compounds with a cardiant, cardiovascular-Gen, antiarrhythmic, antianginal, antiarteriosclerotic, vasotropic or hypotensive activity through action as glucose metabolism regulators or cardiovascular haemodynamics regulators. The invention may be used for the treatment or prevention of an early cardiac or early cardiovascular disease (for example left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, atherosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, **intermittent claudication** (for example atherosclerosis obliterens), diastolic dysfunction and systolic dysfunction) in a diabetic or non-diabetic patient; for the preparation of a pharmaceutical composition for reducing the level of brain natriuretic peptide (BNP) in plasma and/or heart tissue in a diabetic or non-diabetic patient. The invention may also be useful for the treatment of myocardial infarction, acute coronary syndrome, unstable angina, non-Q-wave cardiac necrosis, Q-wave myocardial infarct and morbidity after stroke. The **GLP-1** agonists are in the form of stable derivatives and exhibit a protracted profile of action compared to the corresponding other **GLP-1** analogues. The **GLP-1** analogues lower the brain natriuretic peptide (BNP) in the plasma and/or heart tissue, in addition to lowering blood glucose and plasma lipids. The present sequence is that of an **exendin** peptide which is related to the invention.

L75 ANSWER 35 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADH73029 peptide DGENE
TITLE: Use of a **glucagon like peptide-1** agonist or its salt for the preparation of a pharmaceutical composition for the treatment or prevention of an early cardiac or early cardiovascular disease in a diabetic or non- diabetic patient.
INVENTOR: Knudsen L B; Rolin B C; Carr R D; Selmer J; Larsen J; Elbrond B; Nielsen L B; Christoffersen C
PATENT ASSIGNEE: (NOVO)NOVO NORDISK AS.
PATENT INFO: WO 2003084563 A1 20031016 14p
APPLICATION INFO: WO 2003-DK216 20030402
PRIORITY INFO: DK 2002-499 20020404
US 2002-375255P 20020423
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2004-022543 [02]
DESCRIPTION: **Glucagon like peptide-1** related **exendin** peptide 1.

AN ADH73029 peptide DGENE

AB This invention relates to a novel method for the treatment or prevention of an early cardiac or early cardiovascular disease in a diabetic or non-diabetic patient where a **glucagon like peptide-1** (**GLP 1**) agonist or its salt is used. The invention may be useful for the development of compounds with a cardiant, cardiovascular-Gen, antiarrhythmic, antianginal, antiarteriosclerotic, vasotropic or hypotensive activity through action as glucose metabolism regulators or cardiovascular haemodynamics regulators. The invention may be used for the treatment or

prevention of an early cardiac or early cardiovascular disease (for example left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, atherosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, **intermittent claudication** (for example atherosclerosis obliterens), diastolic dysfunction and systolic dysfunction) in a diabetic or non-diabetic patient; for the preparation of a pharmaceutical composition for reducing the level of brain natriuretic peptide (BNP) in plasma and/or heart tissue in a diabetic or non-diabetic patient. The invention may also be useful for the treatment of myocardial infarction, acute coronary syndrome, unstable angina, non-Q-wave cardiac necrosis, Q-wave myocardial infarct and morbidity after stroke. The **GLP-1** agonists are in the form of stable derivatives and exhibit a protracted profile of action compared to the corresponding other **GLP-1** analogues. The **GLP-1** analogues lower the brain natriuretic peptide (BNP) in the plasma and/or heart tissue, in addition to lowering blood glucose and plasma lipids. The present sequence is that of an **exendin** peptide which is related to the invention.

L75 ANSWER 36 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADB84200 peptide DGENE
TITLE: Method for the treatment or prevention of **intermittent claudication** or **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.
INVENTOR: Hathaway D R; Coolidge T R
PATENT ASSIGNEE: (HATH-I) HATHAWAY D R.
(COOL-I) COOLIDGE T R.
PATENT INFO: US 2003073626 A1 20030417 12p
APPLICATION INFO: US 2002-91258 20020305
PRIORITY INFO: US 1999-302596 19990430
US 2001-851738 20010509
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-677986 [64]
DESCRIPTION: **Glucagon-like peptide-1**, **GLP-1**(7-36).
AN ADB84200 peptide DGENE
AB The ivention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide-1** (**GLP-1**) molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from peripheral vascular disease (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide-1** peptide **GLP-1**(1-37) that can be used in the method of the invention.

L75 ANSWER 37 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADB84202 peptide DGENE
TITLE: Method for the treatment or prevention of **intermittent claudication** or **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.

INVENTOR: Hathaway D R; Coolidge T R
PATENT ASSIGNEE: (HATH-I)HATHAWAY D R.
(COOL-I) COOLIDGE T R.
PATENT INFO: US 2003073626 A1 20030417 12p
APPLICATION INFO: US 2002-91258 20020305
PRIORITY INFO: US 1999-302596 19990430
US 2001-851738 20010509
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-677986 [64]
DESCRIPTION: **Glucagon-like peptide-1**
, **GLP-1**(9-36).
AN ADB84202 peptide DGENE
AB The ivention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide -1** (**GLP-1**) molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from peripheral vascular disease (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide-1** peptide **GLP-1**(1-37) that can be used in the method of the invention.

L75 ANSWER 38 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADB84201 peptide DGENE
TITLE: Method for the treatment or prevention of **intermittent claudication** or **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.
INVENTOR: Hathaway D R; Coolidge T R
PATENT ASSIGNEE: (HATH-I)HATHAWAY D R.
(COOL-I) COOLIDGE T R.
PATENT INFO: US 2003073626 A1 20030417 12p
APPLICATION INFO: US 2002-91258 20020305
PRIORITY INFO: US 1999-302596 19990430
US 2001-851738 20010509
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-677986 [64]
DESCRIPTION: **Glucagon-like peptide-1**
, **GLP-1**(9-37).
AN ADB84201 peptide DGENE
AB The ivention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide -1** (**GLP-1**) molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from peripheral vascular disease (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide-1** peptide **GLP-1**(1-37) that can be used in the method of the invention.

L75 ANSWER 39 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADB84198 peptide DGENE

TITLE: Method for the treatment or prevention of **intermittent claudication** or **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.
INVENTOR: Hathaway D R; Coolidge T R
PATENT ASSIGNEE: (HATH-I) HATHAWAY D R.
(COOL-I) COOLIDGE T R.
PATENT INFO: US 2003073626 A1 20030417 12p
APPLICATION INFO: US 2002-91258 20020305
PRIORITY INFO: US 1999-302596 19990430
US 2001-851738 20010509
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-677986 [64]
DESCRIPTION: **Glucagon-like peptide-1**, **GLP-1**(1-36).

AN ADB84198 peptide DGENE

AB The ivention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide-1** (**GLP-1**) molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from peripheral vascular disease (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide-1** peptide **GLP-1**(1-37) that can be used in the method of the invention.

L75 ANSWER 40 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADB84197 peptide DGENE
TITLE: Method for the treatment or prevention of **intermittent claudication** or **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.
INVENTOR: Hathaway D R; Coolidge T R
PATENT ASSIGNEE: (HATH-I) HATHAWAY D R.
(COOL-I) COOLIDGE T R.
PATENT INFO: US 2003073626 A1 20030417 12p
APPLICATION INFO: US 2002-91258 20020305
PRIORITY INFO: US 1999-302596 19990430
US 2001-851738 20010509
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-677986 [64]
DESCRIPTION: **Glucagon-like peptide-1**, **GLP-1**(1-37).

AN ADB84197 peptide DGENE

AB The ivention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide-1** (**GLP-1**) molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from peripheral vascular disease (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian

glucagon-like peptide-1 peptide **GLP-1**(1-37) that can be used in the method of the invention.

L75 ANSWER 41 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADB84207 peptide DGENE
TITLE: Method for the treatment or prevention of **intermittent claudication** or **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.
INVENTOR: Hathaway D R; Coolidge T R
PATENT ASSIGNEE: (HATH-I) HATHAWAY D R.
(COOL-I) COOLIDGE T R.
PATENT INFO: US 2003073626 A1 20030417 12p
APPLICATION INFO: US 2002-91258 20020305
PRIORITY INFO: US 1999-302596 19990430
US 2001-851738 20010509
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-677986 [64]
DESCRIPTION: Gila monster venom helospectin II.
AN ADB84207 peptide DGENE
AB The ivention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide -1** (**GLP-1**) molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from peripheral vascular disease (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide-1** peptide **GLP-1**(1-37) that can be used in the method of the invention.

L75 ANSWER 42 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADB84209 peptide DGENE
TITLE: Method for the treatment or prevention of **intermittent claudication** or **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.
INVENTOR: Hathaway D R; Coolidge T R
PATENT ASSIGNEE: (HATH-I) HATHAWAY D R.
(COOL-I) COOLIDGE T R.
PATENT INFO: US 2003073626 A1 20030417 12p
APPLICATION INFO: US 2002-91258 20020305
PRIORITY INFO: US 1999-302596 19990430
US 2001-851738 20010509
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-677986 [64]
DESCRIPTION: Gila monster venom Q8,Q9 helodermin.
AN ADB84209 peptide DGENE
AB The ivention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide -1** (**GLP-1**) molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a

human subject suffering from peripheral vascular disease (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide-1** peptide **GLP-1**(1-37) that can be used in the method of the invention.

L75 ANSWER 43 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADB84199 peptide DGENE
TITLE: Method for the treatment or prevention of **intermittent claudication** or **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.
INVENTOR: Hathaway D R; Coolidge T R
PATENT ASSIGNEE: (HATH-I)HATHAWAY D R.
(COOL-I) COOLIDGE T R.
PATENT INFO: US 2003073626 A1 20030417 12p
APPLICATION INFO: US 2002-91258 20020305
PRIORITY INFO: US 1999-302596 19990430
US 2001-851738 20010509
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-677986 [64]
DESCRIPTION: **Glucagon-like peptide-1**, **GLP-1**(7-37).
AN ADB84199 peptide DGENE
AB The ivention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide-1** (**GLP-1**) molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from peripheral vascular disease (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide-1** peptide **GLP-1**(1-37) that can be used in the method of the invention.

L75 ANSWER 44 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADB84204 peptide DGENE
TITLE: Method for the treatment or prevention of **intermittent claudication** or **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.
INVENTOR: Hathaway D R; Coolidge T R
PATENT ASSIGNEE: (HATH-I)HATHAWAY D R.
(COOL-I) COOLIDGE T R.
PATENT INFO: US 2003073626 A1 20030417 12p
APPLICATION INFO: US 2002-91258 20020305
PRIORITY INFO: US 1999-302596 19990430
US 2001-851738 20010509
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-677986 [64]
DESCRIPTION: Gila monster venom **exendin** 4 (9-39(NH2)).
AN ADB84204 peptide DGENE
AB The ivention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury

caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide -1** (**GLP-1**) molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from peripheral vascular disease (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide-1** peptide **GLP-1**(1-37) that can be used in the method of the invention.

L75 ANSWER 45 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADB84205 peptide DGENE
TITLE: Method for the treatment or prevention of **intermittent claudication** or **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.
INVENTOR: Hathaway D R; Coolidge T R
PATENT ASSIGNEE: (HATH-I)HATHAWAY D R.
(COOL-I) COOLIDGE T R.
PATENT INFO: US 2003073626 A1 20030417 12p
APPLICATION INFO: US 2002-91258 20020305
PRIORITY INFO: US 1999-302596 19990430
US 2001-851738 20010509
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-677986 [64]
DESCRIPTION: Gila monster venom **exendin** 4.
AN ADB84205 peptide DGENE
AB The ivention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide -1** (**GLP-1**) molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from peripheral vascular disease (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide-1** peptide **GLP-1**(1-37) that can be used in the method of the invention.

L75 ANSWER 46 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADB84206 peptide DGENE
TITLE: Method for the treatment or prevention of **intermittent claudication** or **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.
INVENTOR: Hathaway D R; Coolidge T R
PATENT ASSIGNEE: (HATH-I)HATHAWAY D R.
(COOL-I) COOLIDGE T R.
PATENT INFO: US 2003073626 A1 20030417 12p
APPLICATION INFO: US 2002-91258 20020305
PRIORITY INFO: US 1999-302596 19990430
US 2001-851738 20010509
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-677986 [64]

DESCRIPTION: Gila monster venom helospectin I.
AN ADB84206 peptide DGENE
AB The ivention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide -1 (GLP-1)** molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from peripheral vascular disease (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide-1** peptide **GLP-1**(1-37) that can be used in the method of the invention.

L75 ANSWER 47 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADB84203 peptide DGENE
TITLE: Method for the treatment or prevention of **intermittent claudication** or **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.
INVENTOR: Hathaway D R; Coolidge T R
PATENT ASSIGNEE: (HATH-I) HATHAWAY D R.
(COOL-I) COOLIDGE T R.
PATENT INFO: US 2003073626 A1 20030417 12p
APPLICATION INFO: US 2002-91258 20020305
PRIORITY INFO: US 1999-302596 19990430
US 2001-851738 20010509
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-677986 [64]
DESCRIPTION: Gila monster venom **exendin** 3.
AN ADB84203 peptide DGENE
AB The ivention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide -1 (GLP-1)** molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from peripheral vascular disease (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide-1** peptide **GLP-1**(1-37) that can be used in the method of the invention.

L75 ANSWER 48 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: ADB84208 peptide DGENE
TITLE: Method for the treatment or prevention of **intermittent claudication** or **skeletal muscle injury** caused by **ischemia** and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.
INVENTOR: Hathaway D R; Coolidge T R
PATENT ASSIGNEE: (HATH-I) HATHAWAY D R.
(COOL-I) COOLIDGE T R.
PATENT INFO: US 2003073626 A1 20030417 12p
APPLICATION INFO: US 2002-91258 20020305
PRIORITY INFO: US 1999-302596 19990430

US 2001-851738 20010509
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-677986 [64]
DESCRIPTION: Gila monster venom helodermin.
AN ADB84208 peptide DGENE
AB The ivention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide -1** (**GLP-1**) molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from peripheral vascular disease (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide-1** peptide **GLP-1**(1-37) that can be used in the method of the invention.

L75 ANSWER 49 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: AAU08765 Peptide DGENE
TITLE: Use of **glucagon-like peptide-1** agonist for manufacturing a medicament for lowering total serum lipids e.g. low density lipoproteins and cholesterol -
INVENTOR: Knudsen L B; Selmer J; Sturis J; Larsen P J
PATENT ASSIGNEE: (NOVO)NOVO NORDISK AS.
PATENT INFO: WO 2001066135 A1 20010913 52p
APPLICATION INFO: WO 2001-DK150 20010308
PRIORITY INFO: DK 2000-375 20000308
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-602602 [68]
DESCRIPTION: Human **exendin**-4 polypeptide fragment.
AN AAU08765 Peptide DGENE
AB The invention relates to a medicament for lowering serum lipids, comprising a **glucagon-like peptide 1** (**GLP-1**) agonist. The **GLP-1** agonist is used for lowering total serum lipids such as low density lipoproteins particularly small, dense lipoproteins, triglycerides, cholesterol and non-esterified fatty acids, for increasing high density lipoproteins, for lowering plasma levels of lipoprotein, for inhibiting generation of apolipoprotein, for treating dyslipidaemia in humans and also for lowering fatty acids, such as free fatty acids and non-esterified fatty acids. The medicament is also useful for treating cerebrovascular diseases and cardiovascular diseases such as stroke, cerebral haemorrhage, coronary heart disease, coronary artery disease, diabetic vasculopathy, atherosclerosis, peripheral atherosclerosis, arteriosclerosis, myocardial infarction, ischaemic heart disease, restenosis, peripheral artery disease, angina pectoris, **intermittent claudication**, aneurysms of aorta and other large arteries, bypass graft stenosis and diabetes mellitus. The peptides may also be used in anticoagulative treatment e.g. following a coronary thrombosis or after surgery. This sequence represents a fragment of the **exendin**-4 polypeptide, a **GLP-1** agonist.

L75 ANSWER 50 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: AAU08764 Peptide DGENE
TITLE: Use of **glucagon-like peptide-1** agonist for manufacturing a medicament for lowering total serum lipids e.g. low density lipoproteins and cholesterol -
INVENTOR: Knudsen L B; Selmer J; Sturis J; Larsen P J
PATENT ASSIGNEE: (NOVO)NOVO NORDISK AS.

PATENT INFO: WO 2001066135 A1 20010913 52p
APPLICATION INFO: WO 2001-DK150 20010308
PRIORITY INFO: DK 2000-375 20000308
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-602602 [68]
DESCRIPTION: Human **exendin**-3 polypeptide fragment.
AN AAU08764 Peptide DGENE
AB The invention relates to a medicament for lowering serum lipids, comprising a **glucagon-like peptide 1** (**GLP-1**) agonist. The **GLP-1** agonist is used for lowering total serum lipids such as low density lipoproteins particularly small, dense lipoproteins, triglycerides, cholesterol and non-esterified fatty acids, for increasing high density lipoproteins, for lowering plasma levels of lipoprotein, for inhibiting generation of apolipoprotein, for treating dyslipidaemia in humans and also for lowering fatty acids, such as free fatty acids and non-esterified fatty acids. The medicament is also useful for treating cerebrovascular diseases and cardiovascular diseases such as stroke, cerebral haemorrhage, coronary heart disease, coronary artery disease, diabetic vasculopathy, atherosclerosis, peripheral atherosclerosis, arteriosclerosis, myocardial infarction, ischaemic heart disease, restenosis, peripheral artery disease, angina pectoris, **intermittent claudication**, aneurysms of aorta and other large arteries, bypass graft stenosis and diabetes mellitus. The peptides may also be used in anticoagulative treatment e.g. following a coronary thrombosis or after surgery. This sequence represents a fragment of the **exendin**-3 polypeptide, a **GLP-1** agonist.

L75 ANSWER 51 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: AAU08763 Peptide DGENE
TITLE: Use of **glucagon-like peptide-1** agonist for manufacturing a medicament for lowering total serum lipids e.g. low density lipoproteins and cholesterol -
INVENTOR: Knudsen L B; Selmer J; Sturis J; Larsen P J
PATENT ASSIGNEE: (NOVO)NOVO NORDISK AS.
PATENT INFO: WO 2001066135 A1 20010913 52p
APPLICATION INFO: WO 2001-DK150 20010308
PRIORITY INFO: DK 2000-375 20000308
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-602602 [68]
DESCRIPTION: Human **exendin** degenerate peptide fragment.
AN AAU08763 Peptide DGENE
AB The invention relates to a medicament for lowering serum lipids, comprising a **glucagon-like peptide 1** (**GLP-1**) agonist. The **GLP-1** agonist is used for lowering total serum lipids such as low density lipoproteins particularly small, dense lipoproteins, triglycerides, cholesterol and non-esterified fatty acids, for increasing high density lipoproteins, for lowering plasma levels of lipoprotein, for inhibiting generation of apolipoprotein, for treating dyslipidaemia in humans and also for lowering fatty acids, such as free fatty acids and non-esterified fatty acids. The medicament is also useful for treating cerebrovascular diseases and cardiovascular diseases such as stroke, cerebral haemorrhage, coronary heart disease, coronary artery disease, diabetic vasculopathy, atherosclerosis, peripheral atherosclerosis, arteriosclerosis, myocardial infarction, ischaemic heart disease, restenosis, peripheral artery disease, angina pectoris, **intermittent claudication**, aneurysms of aorta and other large arteries, bypass graft stenosis and diabetes mellitus. The peptides may also be used in anticoagulative treatment e.g. following a coronary thrombosis or after surgery. This sequence represents a fragment of a degenerate **exendin** polypeptide, a **GLP-1** agonist.

L75 ANSWER 52 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: AAU08762 Peptide DGENE
TITLE: Use of **glucagon-like peptide**-**1** agonist for manufacturing a medicament for lowering total serum lipids e.g. low density lipoproteins and cholesterol -
INVENTOR: Knudsen L B; Selmer J; Sturis J; Larsen P J
PATENT ASSIGNEE: (NOVO)NOVO NORDISK AS.
PATENT INFO: WO 2001066135 A1 20010913 52p
APPLICATION INFO: WO 2001-DK150 20010308
PRIORITY INFO: DK 2000-375 20000308
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-602602 [68]
DESCRIPTION: Human **glucagon-like peptide** **1** (**GLP-1**) agonist sequence #6.

AN AAU08762 Peptide DGENE
AB The invention relates to a medicament for lowering serum lipids, comprising a **glucagon-like peptide** **1** (**GLP-1**) agonist. The **GLP**-**1** agonist is used for lowering total serum lipids such as low density lipoproteins particularly small, dense lipoproteins, triglycerides, cholesterol and non-esterified fatty acids, for increasing high density lipoproteins, for lowering plasma levels of lipoprotein, for inhibiting generation of apolipoprotein, for treating dyslipidaemia in humans and also for lowering fatty acids, such as free fatty acids and non-esterified fatty acids. The medicament is also useful for treating cerebrovascular diseases and cardiovascular diseases such as stroke, cerebral haemorrhage, coronary heart disease, coronary artery disease, diabetic vasculopathy, atherosclerosis, peripheral atherosclerosis, arteriosclerosis, myocardial infarction, ischaemic heart disease, restenosis, peripheral artery disease, angina pectoris, **intermittent claudication**, aneurysms of aorta and other large arteries, bypass graft stenosis and diabetes mellitus. The peptides may also be used in anticoagulative treatment e.g. following a coronary thrombosis or after surgery. This sequence represents a **GLP**-**1** peptide agonist.

L75 ANSWER 53 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: AAU08761 Peptide DGENE
TITLE: Use of **glucagon-like peptide**-**1** agonist for manufacturing a medicament for lowering total serum lipids e.g. low density lipoproteins and cholesterol -
INVENTOR: Knudsen L B; Selmer J; Sturis J; Larsen P J
PATENT ASSIGNEE: (NOVO)NOVO NORDISK AS.
PATENT INFO: WO 2001066135 A1 20010913 52p
APPLICATION INFO: WO 2001-DK150 20010308
PRIORITY INFO: DK 2000-375 20000308
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-602602 [68]
DESCRIPTION: Human **glucagon-like peptide** **1** (**GLP-1**) agonist sequence #5.

AN AAU08761 Peptide DGENE
AB The invention relates to a medicament for lowering serum lipids, comprising a **glucagon-like peptide** **1** (**GLP-1**) agonist. The **GLP**-**1** agonist is used for lowering total serum lipids such as low density lipoproteins particularly small, dense lipoproteins, triglycerides, cholesterol and non-esterified fatty acids, for increasing high density lipoproteins, for lowering plasma levels of lipoprotein, for inhibiting generation of apolipoprotein, for treating dyslipidaemia in humans and also for lowering fatty acids, such as free fatty acids and non-esterified fatty acids. The medicament is also useful for treating

cerebrovascular diseases and cardiovascular diseases such as stroke, cerebral haemorrhage, coronary heart disease, coronary artery disease, diabetic vasculopathy, atherosclerosis, peripheral atherosclerosis, arteriosclerosis, myocardial infarction, ischaemic heart disease, restenosis, peripheral artery disease, angina pectoris, **intermittent claudication**, aneurysms of aorta and other large arteries, bypass graft stenosis and diabetes mellitus. The peptides may also be used in anticoagulative treatment e.g. following a coronary thrombosis or after surgery. This sequence represents a **GLP-1** peptide agonist.

L75 ANSWER 54 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: AAU08760 Peptide DGENE
TITLE: Use of **glucagon-like peptide-1** agonist for manufacturing a medicament for lowering total serum lipids e.g. low density lipoproteins and cholesterol -
INVENTOR: Knudsen L B; Selmer J; Sturis J; Larsen P J
PATENT ASSIGNEE: (NOVO)NOVO NORDISK AS.
PATENT INFO: WO 2001066135 A1 20010913 52p
APPLICATION INFO: WO 2001-DK150 20010308
PRIORITY INFO: DK 2000-375 20000308
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-602602 [68]
DESCRIPTION: Human **glucagon-like peptide 1** (**GLP-1**) agonist sequence #4.

AN AAU08760 Peptide DGENE
AB The invention relates to a medicament for lowering serum lipids, comprising a **glucagon-like peptide 1** (**GLP-1**) agonist. The **GLP-1** agonist is used for lowering total serum lipids such as low density lipoproteins particularly small, dense lipoproteins, triglycerides, cholesterol and non-esterified fatty acids, for increasing high density lipoproteins, for lowering plasma levels of lipoprotein, for inhibiting generation of apolipoprotein, for treating dyslipidaemia in humans and also for lowering fatty acids, such as free fatty acids and non-esterified fatty acids. The medicament is also useful for treating cerebrovascular diseases and cardiovascular diseases such as stroke, cerebral haemorrhage, coronary heart disease, coronary artery disease, diabetic vasculopathy, atherosclerosis, peripheral atherosclerosis, arteriosclerosis, myocardial infarction, ischaemic heart disease, restenosis, peripheral artery disease, angina pectoris, **intermittent claudication**, aneurysms of aorta and other large arteries, bypass graft stenosis and diabetes mellitus. The peptides may also be used in anticoagulative treatment e.g. following a coronary thrombosis or after surgery. This sequence represents a **GLP-1** peptide agonist.

L75 ANSWER 55 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: AAU08759 Peptide DGENE
TITLE: Use of **glucagon-like peptide-1** agonist for manufacturing a medicament for lowering total serum lipids e.g. low density lipoproteins and cholesterol -
INVENTOR: Knudsen L B; Selmer J; Sturis J; Larsen P J
PATENT ASSIGNEE: (NOVO)NOVO NORDISK AS.
PATENT INFO: WO 2001066135 A1 20010913 52p
APPLICATION INFO: WO 2001-DK150 20010308
PRIORITY INFO: DK 2000-375 20000308
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-602602 [68]
DESCRIPTION: Human **glucagon-like peptide 1** (**GLP-1**) agonist sequence #3.

AN AAU08759 Peptide DGENE

AB The invention relates to a medicament for lowering serum lipids, comprising a **glucagon-like peptide 1** (**GLP-1**) agonist. The **GLP-1** agonist is used for lowering total serum lipids such as low density lipoproteins particularly small, dense lipoproteins, triglycerides, cholesterol and non-esterified fatty acids, for increasing high density lipoproteins, for lowering plasma levels of lipoprotein, for inhibiting generation of apolipoprotein, for treating dyslipidaemia in humans and also for lowering fatty acids, such as free fatty acids and non-esterified fatty acids. The medicament is also useful for treating cerebrovascular diseases and cardiovascular diseases such as stroke, cerebral haemorrhage, coronary heart disease, coronary artery disease, diabetic vasculopathy, atherosclerosis, peripheral atherosclerosis, arteriosclerosis, myocardial infarction, ischaemic heart disease, restenosis, peripheral artery disease, angina pectoris, **intermittent claudication**, aneurysms of aorta and other large arteries, bypass graft stenosis and diabetes mellitus. The peptides may also be used in anticoagulative treatment e.g. following a coronary thrombosis or after surgery. This sequence represents a **GLP-1** peptide agonist.

L75 ANSWER 56 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: AAU08758 Peptide DGENE
TITLE: Use of **glucagon-like peptide-1** agonist for manufacturing a medicament for lowering total serum lipids e.g. low density lipoproteins and cholesterol -
INVENTOR: Knudsen L B; Selmer J; Sturis J; Larsen P J
PATENT ASSIGNEE: (NOVO)NOVO NORDISK AS.
PATENT INFO: WO 2001066135 A1 20010913 52p
APPLICATION INFO: WO 2001-DK150 20010308
PRIORITY INFO: DK 2000-375 20000308
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-602602 [68]
DESCRIPTION: Human **glucagon-like peptide 1** (**GLP-1**) agonist sequence #2.

AN AAU08758 Peptide DGENE
AB The invention relates to a medicament for lowering serum lipids, comprising a **glucagon-like peptide 1** (**GLP-1**) agonist. The **GLP-1** agonist is used for lowering total serum lipids such as low density lipoproteins particularly small, dense lipoproteins, triglycerides, cholesterol and non-esterified fatty acids, for increasing high density lipoproteins, for lowering plasma levels of lipoprotein, for inhibiting generation of apolipoprotein, for treating dyslipidaemia in humans and also for lowering fatty acids, such as free fatty acids and non-esterified fatty acids. The medicament is also useful for treating cerebrovascular diseases and cardiovascular diseases such as stroke, cerebral haemorrhage, coronary heart disease, coronary artery disease, diabetic vasculopathy, atherosclerosis, peripheral atherosclerosis, arteriosclerosis, myocardial infarction, ischaemic heart disease, restenosis, peripheral artery disease, angina pectoris, **intermittent claudication**, aneurysms of aorta and other large arteries, bypass graft stenosis and diabetes mellitus. The peptides may also be used in anticoagulative treatment e.g. following a coronary thrombosis or after surgery. This sequence represents a **GLP-1** peptide agonist.

L75 ANSWER 57 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: AAU08757 Peptide DGENE
TITLE: Use of **glucagon-like peptide-1** agonist for manufacturing a medicament for lowering total serum lipids e.g. low density lipoproteins and cholesterol -
INVENTOR: Knudsen L B; Selmer J; Sturis J; Larsen P J

PATENT ASSIGNEE: (NOVO)NOVO NORDISK AS.
PATENT INFO: WO 2001066135 A1 20010913 52p
APPLICATION INFO: WO 2001-DK150 20010308
PRIORITY INFO: DK 2000-375 20000308
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-602602 [68]
DESCRIPTION: Human **glucagon-like peptide 1 (GLP-1)** agonist sequence #1.

AN AAU08757 Peptide DGENE

AB The invention relates to a medicament for lowering serum lipids, comprising a **glucagon-like peptide 1 (GLP-1)** agonist. The **GLP-1** agonist is used for lowering total serum lipids such as low density lipoproteins particularly small, dense lipoproteins, triglycerides, cholesterol and non-esterified fatty acids, for increasing high density lipoproteins, for lowering plasma levels of lipoprotein, for inhibiting generation of apolipoprotein, for treating dyslipidaemia in humans and also for lowering fatty acids, such as free fatty acids and non-esterified fatty acids. The medicament is also useful for treating cerebrovascular diseases and cardiovascular diseases such as stroke, cerebral haemorrhage, coronary heart disease, coronary artery disease, diabetic vasculopathy, atherosclerosis, peripheral atherosclerosis, arteriosclerosis, myocardial infarction, ischaemic heart disease, restenosis, peripheral artery disease, angina pectoris, **intermittent claudication**, aneurysms of aorta and other large arteries, bypass graft stenosis and diabetes mellitus. The peptides may also be used in anticoagulative treatment e.g. following a coronary thrombosis or after surgery. This sequence represents a **GLP-1** peptide agonist.

L75 ANSWER 58 OF 58 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: AAU08756 Peptide DGENE
TITLE: Use of **glucagon-like peptide-1** agonist for manufacturing a medicament for lowering total serum lipids e.g. low density lipoproteins and cholesterol -
INVENTOR: Knudsen L B; Selmer J; Sturis J; Larsen P J
PATENT ASSIGNEE: (NOVO)NOVO NORDISK AS.
PATENT INFO: WO 2001066135 A1 20010913 52p
APPLICATION INFO: WO 2001-DK150 20010308
PRIORITY INFO: DK 2000-375 20000308
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-602602 [68]
DESCRIPTION: Human **glucagon-like peptide 1 (GLP-1)** agonist degenerate sequence.

AN AAU08756 Peptide DGENE

AB The invention relates to a medicament for lowering serum lipids, comprising a **glucagon-like peptide 1 (GLP-1)** agonist. The **GLP-1** agonist is used for lowering total serum lipids such as low density lipoproteins particularly small, dense lipoproteins, triglycerides, cholesterol and non-esterified fatty acids, for increasing high density lipoproteins, for lowering plasma levels of lipoprotein, for inhibiting generation of apolipoprotein, for treating dyslipidaemia in humans and also for lowering fatty acids, such as free fatty acids and non-esterified fatty acids. The medicament is also useful for treating cerebrovascular diseases and cardiovascular diseases such as stroke, cerebral haemorrhage, coronary heart disease, coronary artery disease, diabetic vasculopathy, atherosclerosis, peripheral atherosclerosis, arteriosclerosis, myocardial infarction, ischaemic heart disease, restenosis, peripheral artery disease, angina pectoris, **intermittent claudication**, aneurysms of aorta and other large arteries, bypass graft stenosis and diabetes mellitus. The peptides

may also be used in anticoagulative treatment e.g. following a coronary thrombosis or after surgery. This sequence represents a degenerate **GLP-1** peptide agonist.

=>